Managing Cancer and Living Meaningfully (CALM): A Study to Evaluate the Effectiveness of a Psychological Intervention for Cancer Patients

Phase 3

Completed

• Conditions: Depression
• Interventions: Behavioral: CALM

• Registration Number: NCT01506492
• Lead Sponsor: University Health Network, Toronto

Brief Summary

The purpose of this study is to test the effectiveness of a brief manualized individual psychotherapy, called Managing Cancer and Living Meaningfully (CALM), to reduce distress and promote psychological well-being in patients with various types of cancer, including metastatic disease.

Detailed Description

We have developed and pilot-tested a brief manualized individual psychotherapy, called Managing Cancer and Living Meaningfully (CALM), to reduce distress in patients with various types of cancer, including metastatic disease. We propose to conduct a two-arm randomized controlled trial (RCT) to test the effectiveness of CALM against usual care (UC) for the reduction of distress in patients with various types of cancer, including metastatic disease. Usual care at our center includes routine screening for depression and other distress in oncology outpatient clinics, communication of screening information to the medical treatment team, and referral as needed for non-standardized, and primarily instrumental, psychosocial care and psychiatric assessment and treatment.

The design will be an unblinded RCT consisting of two conditions (CALM and UC), with a baseline assessment and follow-ups at three and six months. The trial will take place in Princess Margaret Cancer Centre, University Health Network, a comprehensive cancer center in Toronto, Canada. Participants will be outpatients with various types of cancer, including metastatic disease.

Study Timeline

• Study Start: 2012-01
• Study First Submitted: 2012-01-04
• Study First Submitted QC: 2012-01-05
• Study First Posted: 2012-01-10
• Primary Completion: 2016-10
• Study Completion: 2016-10
• Status Verified: 2019-09
• Last Update Submitted: 2019-09-26
• Last Update Posted: 2019-09-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 305

Inclusion Criteria

• ≥18 years of age
• Fluency in English
• Confirmed diagnosis of stage III or IV lung cancer; any stage of pancreatic cancer, unresectable cholangiocarcinoma, unresectable liver cancer, unresectable ampullary/peri-ampullary cancer, or other stage IV (metastatic) gastrointestinal cancer; stage III or IV ovarian and fallopian tube cancers, or other stage IV gynecological cancers; and stage IV breast, genitourinary, sarcoma, melanoma or endocrine cancers (all with expected survival of 12-18 months)

Read More

Exclusion Criteria

• Major communication difficulties (including language barriers)
• Inability to commit to the required 3-6 psychotherapy sessions
• Cognitive impairment indicated in the medical record, or by the attending oncologist, or as indicated by a score < 20 on the Short Orientation-Memory-Concentration test, unless deemed suitable at the recruiter's discretion
• Actively seeing a psychiatrist or psychologist in the Department of Supportive Care (formerly the Department of Psychosocial Oncology and Palliative Care) at Princess Margaret Cancer Centre at the time of study approach

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
CALM	CALM	Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.

Primary Outcome Measures

Name	Time	Method
Patient Health Questionnaire-9 (PHQ-9)	6-months	A reliable and valid 9-item measure of depression that has been used widely with advanced cancer patients.

Secondary Outcome Measures

Name	Time	Method
Death and Dying Distress Scale (DADDS)	6-months	A recently developed, 15-item measure assessing death anxiety in patients with advanced cancer.
Clinical Evaluation Questionnaire (CEQ)	6-months	A 7-item measure evaluating the extent to which patients felt emotionally supported by the clinical services provided.
Quality of Life at the End of Life-Cancer Scale (QUAL-EC)	6-months	A measure of quality of life in patient populations near the end of life.
Posttraumatic Growth Inventory (PTGI)	6-months	A 21-item self-report scale that measures positive psychological changes after trauma. It has been used as a measure of psychological growth in cancer and as an outcome measure for intervention studies.
Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being Scale (FACIT-Sp)	6-months	A 12-item self-report measure of spiritual well-being, assessing spiritual meaning and peace, and faith, that has been widely used in palliative care research.
Structured Clinical Interview for DSM Disorders (SCID)-Research Version	6-months	A semi-structured interview that allows researchers to make clinical diagnoses according to DSM criteria. Portions of the Mood Disorders and Optional Disorders modules will be administered: major depressive episode and minor depressive disorder.
Generalized Anxiety Disorders-7 (GAD-7)	6-months	A widely used and validated 7-item self-report measure designed to screen and assess the severity of GAD symptoms.
Demoralization Scale (DS)	6-months	A 24-item self-report measure that assesses one aspect of existential distress, which includes loss of meaning and purpose, disheartenment and helplessness.
Experiences in Close Relationships Inventory Modified Short Form Version (ECR-M-16)	6-months	A 16-item self-report measure of attachment security.
Couple Communication Scale (CCS)	6-months	A measure for participants who are married, common-law, or in a long-term relationship. This measure is concerned with an individual's feelings, beliefs, and attitudes about the communication in his/her relationship.

Trial Locations

Locations (1)

Princess Margaret Cancer Centre; 🇨🇦 Toronto, Ontario, Canada